New drug vs chemo for platinum-resistant ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of ovarian, fallopian tube, or primary peritoneal cancer called high-grade serous.
- Your cancer must have stopped responding to platinum-based chemotherapy (like carboplatin) within 6 months of your last dose.
- You have received between 1 and 4 types of prior cancer treatments, and your doctor thinks single chemotherapy is a reasonable next step.
- You must have had treatment with bevacizumab (if safe for you) and also mirvetuximab soravtansine (if your tumor had a certain marker), unless there was a medical reason not to.
- You have at least one tumor that can be measured on a scan (per RECIST 1.1).
- A tissue sample from your tumor that is less than 5 years old must be available, or you must be willing to have a new biopsy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new pill called INCB123667 for people with a type of ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if the drug can shrink tumors or slow their growth.
This trial is testing a new drug (SHR-A1811) versus standard chemotherapy for women with platinum-resistant ovarian cancer. The study looks at a specific protein (HER2) to see if the new treatment can help slow or stop the cancer.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This trial tests a new drug called azenosertib against standard chemotherapy for ovarian, fallopian tube, or peritoneal cancer that has come back after platinum-based treatment. The drug targets a specific protein (cyclin E1) found in some tumors and may help stop cancer cells from dividing.
This trial tests a different way of giving chemotherapy to people with advanced ovarian cancer that didn't respond well to initial treatment. The goal is to see if changing the dose and schedule can improve outcomes.
This study tests whether adding a new pill (INCB123667) to the usual maintenance drug bevacizumab (Avastin) can keep ovarian cancer from coming back, compared to bevacizumab alone. It is for women who have finished their first chemo and are in remission or have stable disease.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.